Results for “”

Entry Author Date Location
Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More 02/21/20 National
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More 02/14/20 National
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks 02/13/20 National
Ligand’s Icagen Deal Brings Neuro, CF Assets Plus Partnering Potential 02/12/20 San Diego
Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. 02/11/20 National
Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s 02/10/20 National
Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More 02/07/20 National
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA 02/04/20 National
United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial 02/03/20 National
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy 01/31/20 San Francisco
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More 01/31/20 National
BIO Report: More Work Needed to Improve Diversity at Biotech Firms 01/30/20 National
Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH 01/28/20 Boston
BioIntelliSense Debuts “Sticker” Sensor to Capture Patient Data Remotely 01/28/20 Boulder/Denver
Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report 01/28/20 National
Life Sciences IPOs Target Collective Raise of More Than $600M This Week 01/27/20 National
Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More 01/24/20 National
Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More 01/17/20 National
FDA Panel Votes Down Nektar Opioid Painkiller, Asks for More Data 01/14/20 National
Biotech Roundup: Drug Pricing Promises, Bone Disease Data, IPO Plans & More 01/10/20 National
Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More 01/03/20 National
No More Fish or Fruit: Intrexon Turns SynBio Focus to Human Health 01/02/20 National
Bio Roundup: Amarin’s Approval, FTC v. Illumina, a $120M Deal & More 12/20/19 National
Zafgen’s Path Forward Is Reverse Merger With Chondrial Therapeutics 12/18/19 Boston
Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More 12/13/19 National
Iterum’s Antibiotic for Super Bugs Falls Short in Phase 3, Shares Sink 12/11/19 National
KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test 12/10/19 Boston
Bio Roundup: Biogen at CTAD, Sage’s Stumble, Astellas’s $3B Offer & More 12/06/19 National
FDA Rejects Enzyvant’s Regenerative Therapy for Rare Immune Disorder 12/05/19 Boston
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal 12/03/19 San Francisco
Page 1 of 47 next page »